ELESTAT® ophthalmic solution is indicated for the prevention of ocular itching associated with allergic conjunctivitis. ELESTAT® ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to epinastine or to any of the other ingredients. Patients should be advised not to wear a contact lens if their eye is red. ELESTAT® ophthalmic solution should not be used to treat contact lens related irritation. The preservatives in ELESTAT®, benzalkonium chloride, may be absorbed by soft ontact lenses. Contact lenses should be removed prior to instillation of ELESTAT® ophthalmic solution and may be reinserted after 10 minutes following its administration. Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from suing contaminated solutions. Bottle should be kept tightly closed when not in use. The most frequently reported ocular adverse events occurring in approximately 1% to 10% of patients were burning sensation in the eye, folliculosis, hyperemia, and pruritus. The most frequently reported nonocular adverse events were infection (cold symptoms and upper respiratory infections), seen in approximately 10% of patients, and headache, rhinitis, sinusitis, increased cough, and pharyngitis seen in approximately 1% to 3% of patients. Some of these events were similar to the underlying disease being studied. Please see Prescribing Information for ELESTAT®.